Vivani Medical's 2025 10-K Reveals $26.6M Net Loss, $24.3M Cash Burn
VANI sits 18% above its 52-week low of $0.905.
Summary
Vivani Medical's 2025 10-K filing reported a net loss of $26.6 million and an operating loss of $27.5 million, with cash used in operating activities totaling $24.3 million. These figures represent a widening of losses compared to the previous year and a significant cash burn relative to the company's market capitalization. This financial update provides the operational context for the company, following recent positive news regarding strong preclinical results for its semaglutide implant. While the company has secured financing to extend its cash runway into mid-2027, traders will need to weigh the substantial cash burn against the promising pipeline developments and the company's ability to reach clinical milestones before needing further capital.
At the time of this announcement, VANI was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.8M. The 52-week trading range was $0.91 to $1.92. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.